PhaseBio Pharmaceuticals Stock Forecast, Price & News

-0.23 (-5.78 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume883,381 shs
Average Volume513,355 shs
Market Capitalization$170.41 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PhaseBio Pharmaceuticals logo

About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.62 out of 5 stars

Medical Sector

423rd out of 2,100 stocks

Pharmaceutical Preparations Industry

203rd out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

Is PhaseBio Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PhaseBio Pharmaceuticals stock.
View analyst ratings for PhaseBio Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than PhaseBio Pharmaceuticals?

Wall Street analysts have given PhaseBio Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PhaseBio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for PhaseBio Pharmaceuticals

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its earnings results on Thursday, May, 13th. The company reported ($0.87) EPS for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.14.
View PhaseBio Pharmaceuticals' earnings history

How has PhaseBio Pharmaceuticals' stock price been impacted by Coronavirus?

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PHAS stock has increased by 19.8% and is now trading at $3.75.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PHAS?

2 analysts have issued 1 year target prices for PhaseBio Pharmaceuticals' stock. Their forecasts range from $8.00 to $15.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $11.00 in the next year. This suggests a possible upside of 193.3% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:
  • Mr. Jonathan P. Mow, Pres, CEO & Director (Age 56, Pay $812.44k)
  • Mr. John P. Sharp, Chief Financial Officer (Age 56, Pay $516.42k)
  • Dr. John S. Lee, Chief Medical Officer (Age 53, Pay $582.23k)
  • Mr. Kristopher L. Hanson, VP, Head of Legal & Corp. Sec. (Age 49)
  • Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 56)
  • Mr. Glen Burkhardt, VP of HR (Age 62)
  • Ms. Lauren Richardson, Global Head of Regulatory Affairs & Quality Assurance

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.27%), Endurant Capital Management LP (4.76%), Rock Springs Capital Management LP (3.42%), BlackRock Inc. (4.14%), Altium Capital Management LP (2.63%) and Sphera Funds Management LTD. (1.65%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, Edmund Harrigan and Glen Burkhardt.
View institutional ownership trends for PhaseBio Pharmaceuticals

Which major investors are selling PhaseBio Pharmaceuticals stock?

PHAS stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, and Morgan Stanley.
View insider buying and selling activity for PhaseBio Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying PhaseBio Pharmaceuticals stock?

PHAS stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Endurant Capital Management LP, Altium Capital Management LP, Sphera Funds Management LTD., Monashee Investment Management LLC, DAFNA Capital Management LLC, Rock Springs Capital Management LP, and Squarepoint Ops LLC. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, and Edmund Harrigan.
View insider buying and selling activity for PhaseBio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $3.75.

How much money does PhaseBio Pharmaceuticals make?

PhaseBio Pharmaceuticals has a market capitalization of $170.41 million and generates $320,000.00 in revenue each year. The company earns $-98,570,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.

How many employees does PhaseBio Pharmaceuticals have?

PhaseBio Pharmaceuticals employs 50 workers across the globe.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is

Where are PhaseBio Pharmaceuticals' headquarters?

PhaseBio Pharmaceuticals is headquartered at 1 Great Valley Parkway Suite 30, Malvern PA, 19355.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at (610) 981-6500 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.